IOR-160

IOR-160 is a small molecule dual inhibitor of Casein Kinase 2 (CK2) and Histone Deacetylase (HDAC) enzymes. Identified as a potent antitumor agent, it exhibits high selectivity for CK2 and broad inhibitory activity against HDAC isoforms 1, 2, 3, and 6. In preclinical models of triple-negative breast cancer (TNBC), IOR-160 has demonstrated the ability to significantly reduce tumor growth and burden without detectable toxicity. Its mechanism of action involves the modulation of critical cellular signaling pathways, specifically the inhibition of AKT phosphorylation and the induction of α-tubulin acetylation. Structural studies indicate that its binding mode to CK2 is highly conserved compared to the known CK2 inhibitor CX-4945.